



29 March 2017

The Manager  
Company Announcements Office  
Australian Securities Exchange Limited  
20 Bridge Street  
Sydney NSW 2000

**cyclo**medica  
**techn**egas  
**ultra**lute

Cyclopharm Ltd  
ABN 74 116 931 250  
Unit 4, 1 The Crescent  
Kingsgrove NSW 2208 Australia  
T 61 2 9541 0411  
F 61 2 9543 0960  
[www.cyclopharm.com.au](http://www.cyclopharm.com.au)

## **CYCLOPHARM STRENGTHENS BOARD**

Radiopharmaceutical company Cyclopharm Limited (ASX: CYC) is pleased to announce the appointments of Mr David Heaney as Chairman of the Company's Board, effective immediately, and Mr Tom McDonald as an additional non-executive Director. Mr McDonald's appointment will be effective 3 April 2017.

These appointments are consistent with the Board's plan to ensure that the company's governance and Director expertise continue to support its growth strategy.

Commenting on the announcement, Mr Heaney said, "Cyclopharm is at a very exciting stage in implementing its growth strategy. The Company's 2016 record results provide clear evidence of the successful implementation of our strategic priorities, which are steadily building a larger, more profitable - company.

"As Chairman, I look forward to leading a Board with expanded capabilities and experience, supporting James McBrayer and his management team as they realise significant shareholder value from expanding sales in new markets.

"I am delighted we have been able to recruit a non-executive Director of Mr McDonald's calibre. The addition of Tom's experience in the financial management and strategic development of Australian and US listed companies and the commercialisation of global technology and pharmaceutical businesses will be invaluable as we progress the US Food & Drug Administration Technegas approval and enter the highly prospective US and other markets," Mr Heaney said.

Currently, Mr McDonald is a non-executive director of ASX-listed WolfStrike Rentals Group Limited, where he is Chairman of the Audit & Risk Committee and a member of the Remunerations Committee. He has previously held senior positions with ASX-listed Allomak Limited, CK Life Sciences Int'l Inc., ASX-listed Lipa Pharmaceuticals Limited and Keycorp Limited. For many years he held global senior executive roles at USA biotech Beckman Instruments Inc both in Australia and overseas.

Mr McDonald holds a Bachelor of Commerce from UNSW, is a Fellow of CPA Australia and is a member of the Australian Institute of Company Directors and Chartered Secretaries Australia.

Mr Heaney has been a non-executive director of the Cyclopharm Board since 2007, and served as the Acting Chairman of the Board until today. Mr Heaney held various senior executive positions with NAB in Australia and the US prior to retiring in 1999. He has been a non-executive Director of several listed and unlisted companies

“The changes to Board membership announced today deliver on Cyclopharm’s commitment to strengthen and renew the Company’s governance to ensure the Board continues to have the skills and expertise to support the business as it enters a high growth phase of its development,” Mr McBrayer said.

**For more information, please contact:**

Mr James McBrayer  
Managing Director, CEO and Company Secretary  
Cyclopharm Limited  
T: +61 (02) 9541 0411

**Cyclopharm Limited**

Cyclopharm is an ASX Listed radiopharmaceutical company servicing the global medical community. The Company’s mission is to provide nuclear medicine and other clinicians with the ability to improve patient care outcomes. Cyclopharm achieves this objective primarily through the provision of its core radiopharmaceutical product, Technegas used in functional lung ventilation imaging.

**Technegas**

The Technegas technology is a structured ultra-fine dispersion of radioactive labeled carbon, produced by using dried Technetium- 99m in a carbon crucible, micro furnaced for a few seconds at around 2,700o C. The resultant gas like substance is inhaled by the patient (lung ventilation) via a breathing apparatus, which then allows multiple views and tomography imaging under a gamma or single photon emission computed tomography (SPECT) camera for evaluating functional ventilation imaging. Historically used in the diagnosis of pulmonary embolism, Technegas, together with advancements in complementary technology to multimodality imaging and analytical software, is being used in other disease states to include COPD, asthma, pulmonary hypertension and certain interventional applications to include lobectomies in lung cancer and lung volume reduction surgery.

**Ultralute™**

Cyclopharm’s patented nuclear medicine technology Ultralute™ extends the useful life of Molybdenum-99 (Mo-99) generators by up to 50%. This technology potentially gives nuclear medicine departments the ability to dramatically improve operating efficiencies and health outcomes for patients. Mo-99 generators are used in diagnostic imaging to harvest Technetium-99m, or Tc-99m, which is the primary isotope used in diagnostic imaging throughout the world. This isotope accounts for approximately 80% of all nuclear medicine diagnostic imaging procedures.